Table 1

Quantification of day of onset, clinical score, and paralysis in EAE experiments

ExperimentGenotypeMice, nDay of onset (95% CI)pMaximum clinical score(95% CI)pParalysis, %p
1lysM-Cre:HIF-1αfl/fl1711.7 (11.0–12.5)0.77f2.71 (2.43–2.98)0.77g23.50.73h
HIF-1αfl/fl2211.4 (11.0–12.0)2.79 (2.54–3.02)31.8
2lysM-Cre:VHLfl/fl207.95 (7.0–9.5)0.90i2.95 (2.32–3.52)0.90j500.99k
VHLfl/fl 158.56 (7.0–10.0)2.82 (2.15–3.47)46.7
3GFAP-Cre:HIF-1αfl/fl 2411.40 (11.0–12.0)0.99 s 2.81 (2.43–3.17)0.99 t 62.50.78 u
HIF-1αfl/fl 2711.29 (11.0–12.0)2.96 (2.64–3.26)55.6
4GFAP-Cre:lysM-Cre:HIF-1αfl/fl 1611.44 (10.5–12.0)0.65 v 2.56 (2.26–2.88)0.98 w 12.50.19 x
HIF-1αfl/fl 1311.98 (11.5–12.5)2.57 (2.27–2.86)38.5
  • Experiment 1: EAE induction in lysM-Cre:HIF-1αfl/fl versus control mice HIF-1αfl/fl. Experiment 2: EAE induction in lysMCre:VHLfl/fl versus control mice VHLfl/fl . Experiment 3: EAE induction in GFAP-Cre:HIF-1αfl/fl versus control mice HIF-1αfl/fl . Experiment 4: EAE induction in GFAP-Cre:lysM-Cre:HIF-1αfl/fl versus control mice HIF-1αfl/fl . Day of onset defined as the first day that the score is ≥0.5. A linear mixed-effects model was used to estimate means and 95% confidence interval (CI) for both day of onset and maximum clinical score for each genotype group. A Fisher’s exact test was used to determine whether there is a significant relationship between genotype and mice that achieve score 3 or higher during the experiment (percentage paralysis). Superscript letters refer to the statistical results in Figures 3A, 3B, 5A and 5B. Results, and Table 2.